Gut bacteria boost? new trial tests probiotic alongside cancer drugs

NCT ID NCT07191405

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding a probiotic called Lactobacillus johnsonii to standard chemotherapy and immunotherapy can help control advanced lung, breast, or stomach cancers. About 156 adults aged 18-75 will be randomly assigned to receive either the probiotic or a placebo alongside their regular treatment. The main goal is to see if the probiotic extends the time before the cancer worsens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Lactobacillus johnsonii (a probiotic bacteria)

What this could lead to

If it works, this could show that adding a specific probiotic to standard cancer treatment helps control tumor growth and improves how well the immune therapy works.

What could go wrong

This is an early-stage trial with only 156 participants, so results may not apply to everyone. The probiotic might not provide any additional benefit over standard treatment, and there is a risk of side effects from the combination therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma lung adenocarcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••